1-4 of 4
Paul Moss, PhD
Close
Sort by
Journal Articles

CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT

Karl S Peggs, Eleni Tholouli, Ronjon Chakraverty, PhD, Emmanouil Nikolousis, PhD, Adrian Bloor, PhD FRCPath, Stephen Devereux, MD PhD FRCPath, Kim H. Orchard, PhD, Charles Crawley, Anne Parker, Stephen P Robinson, PhD, Frederick Chen, MDPhD, Gordon Cook, MD, Richard E Clark, MBBS MD, Kirsty Thomson, Matthew Cobb, Katy Newton, PhD, Simon Thomas, PhD, Paul Moss, PhD
Journal: Blood
Blood (2014) 124 (21): 1109.
https://doi.org/10.1182/blood.V124.21.1109.1109
Published: 2014
Journal Articles

Cancer Germline Antigen-Specific T Cells Are Present and Functional in Many Patients with Multiple Myeloma and Paraproteinaemia.

Oliver Goodyear, PhD, Karen Piper, PhD, Naeem Khan, PhD, Jane Starczynski, PhD, Prem Mahendra, MD, Guy Pratt, MD, Paul Moss, PhD
Journal: Blood
Blood (2006) 108 (11): 3507.
https://doi.org/10.1182/blood.V108.11.3507.3507
Published: 2006
Journal Articles

The Novel PARP Inhibitor, AZD2281, Targets Apoptotic Resistant ATM Mutant CLL Tumours for Cellular Killing.

Victoria Weston, PhD, Claire Baker, BSc, Belinda Austen, BMBCh, Malcolm Taylor, PhD, Paul Moss, PhD, Tanja Stankovic, PhD
Journal: Blood
Blood (2006) 108 (11): 2110.
https://doi.org/10.1182/blood.V108.11.2110.2110
Published: 2006
Journal Articles

ATM Mutations Define a Subset of B-CLL Tumours That Only Partially Correlates with 11q Status and Is Associated with Impaired Patient Survival.

Belinda Austen, MRCP, Christopher Fegan, MD, MRCP, MRCPath, Paul Moss, Phd,MRCP,MRCPath, Tanja Stankovic, Phd
Journal: Blood
Blood (2004) 104 (11): 774.
https://doi.org/10.1182/blood.V104.11.774.774
Published: 2004